CLIN CANCER RES:身体成分预测早期乳腺癌患者化疗毒性反应

2017-07-20 MedSci MedSci原创

较差的身体成分构成(BCM)与不良肿瘤结局有关。对于早期乳腺癌患者,尚缺乏BCM对毒副作用影响的证据。CLIN CANCER RES近期发表了一篇文章,研究BCM与接受蒽环类药物和以紫杉烷为基础的化疗治疗的早期乳腺癌患者治疗相关毒性反应的关系。

较差的身体成分构成(BCM)与不良肿瘤结局有关。对于早期乳腺癌患者,尚缺乏BCM对毒副作用影响的证据。CLIN CANCER RES近期发表了一篇文章,研究BCM与接受蒽环类药物和以紫杉烷为基础的化疗治疗的早期乳腺癌患者治疗相关毒性反应的关系。

作者使用术前CT评估骨骼肌面积(SMA),骨骼肌密度(SMD)以及第三腰椎脂肪组织。计算骨骼肌指数(SMI=SMA/身高2)以及骨骼肌规格(SMG=SMI×SMD)。调整年龄、体表面积后评估BCM与毒性反应之间的相对风险。研究共评估了151例早期乳腺癌患者的BCM。50例患者出现3/4级毒性反应,其中在低SMI,低SMG以及低体重指数的患者中毒性反应显着增加。ROC曲线分析表明SMG是3/4级毒性反应的最佳预测因素。按SMG分为3个水平,最高水平毒性反应率为22%,最低水平毒性反应率为46%。调整了年龄和体表面积后,低SMG与血液和胃肠道3/4级毒性反应以及住院时间显着相关。

文章最后认为,较差的BCM与治疗相关毒性反应增加显着相关。需要进一步的研究了解这些指标是否可以用来更精准地控制化疗剂量以减少治疗相关毒性反应并保证治疗效果。

原始出处:
Shlomit Strulov Shachar,Allison M.Deal,et al.Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline and Taxane-Based Chemotherapy for Early-Stage Breast Cancer.CLIN CANCER RES.July 2017 doi:10.1158/1078-0432.CCR-16-2266

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1537409, encodeId=c5c6153e40965, content=<a href='/topic/show?id=b1f09320892' target=_blank style='color:#2F92EE;'>#身体成分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93208, encryptionId=b1f09320892, topicName=身体成分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ac12863902, createdName=chengjn, createdTime=Sat Jul 22 08:34:00 CST 2017, time=2017-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571050, encodeId=3f4c15e1050b7, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Jul 22 08:34:00 CST 2017, time=2017-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224521, encodeId=8dc92245212d, content=学习了学习了学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Fri Jul 21 07:38:09 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224361, encodeId=8c4c224361b9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Thu Jul 20 20:14:39 CST 2017, time=2017-07-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1537409, encodeId=c5c6153e40965, content=<a href='/topic/show?id=b1f09320892' target=_blank style='color:#2F92EE;'>#身体成分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93208, encryptionId=b1f09320892, topicName=身体成分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ac12863902, createdName=chengjn, createdTime=Sat Jul 22 08:34:00 CST 2017, time=2017-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571050, encodeId=3f4c15e1050b7, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Jul 22 08:34:00 CST 2017, time=2017-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224521, encodeId=8dc92245212d, content=学习了学习了学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Fri Jul 21 07:38:09 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224361, encodeId=8c4c224361b9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Thu Jul 20 20:14:39 CST 2017, time=2017-07-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1537409, encodeId=c5c6153e40965, content=<a href='/topic/show?id=b1f09320892' target=_blank style='color:#2F92EE;'>#身体成分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93208, encryptionId=b1f09320892, topicName=身体成分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ac12863902, createdName=chengjn, createdTime=Sat Jul 22 08:34:00 CST 2017, time=2017-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571050, encodeId=3f4c15e1050b7, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Jul 22 08:34:00 CST 2017, time=2017-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224521, encodeId=8dc92245212d, content=学习了学习了学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Fri Jul 21 07:38:09 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224361, encodeId=8c4c224361b9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Thu Jul 20 20:14:39 CST 2017, time=2017-07-20, status=1, ipAttribution=)]
    2017-07-21 hfuym10906

    学习了学习了学习了学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1537409, encodeId=c5c6153e40965, content=<a href='/topic/show?id=b1f09320892' target=_blank style='color:#2F92EE;'>#身体成分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93208, encryptionId=b1f09320892, topicName=身体成分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ac12863902, createdName=chengjn, createdTime=Sat Jul 22 08:34:00 CST 2017, time=2017-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571050, encodeId=3f4c15e1050b7, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Jul 22 08:34:00 CST 2017, time=2017-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224521, encodeId=8dc92245212d, content=学习了学习了学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Fri Jul 21 07:38:09 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224361, encodeId=8c4c224361b9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Thu Jul 20 20:14:39 CST 2017, time=2017-07-20, status=1, ipAttribution=)]
    2017-07-20 184****9840

    学习了受益匪浅

    0

相关资讯

NEJM:早期乳腺癌的局部淋巴结放疗

背景:大部分保乳手术后的乳腺癌患者要接受全乳放射治疗,本实验拟研究在全乳放疗基础上增加局部淋巴结放疗是否会改善乳腺癌的治疗效果。方法:我们随机选取了淋巴结阳性或者高危的淋巴结阴性乳腺癌患者。她们都进行了保乳手术,术后进行系统辅助治疗。将这些患者分为淋巴结放疗组即全乳照射加局部淋巴结放疗(其中包括内乳淋巴结,锁骨上淋巴结及腋窝淋巴结)和对照组即全乳照光。主要研究结果为总体生存率,次要结果为无病生存率

一周研究进展荟萃:锻炼和限制热量哪个才是减肥王道?!

1.BMC Public Health:仅通过锻炼并不能减肥,限制热量才是王道!体育运动对机体的健康有诸多益处,包括减少心脏病、糖尿病以及癌症的发病风险,改善机体的心理健康及情绪。但是与公众的看法相反,一群医学博士则认为锻炼并不能有助于减肥。Dr. Luke和Dr. Cooper的研究以压倒性的证据表明体育活动并不是减肥的关键。食品及饮料行业试图通过推广缺乏锻炼是导致肥胖的主要原因的观点来转移

JAMA Oncology:短疗程大剂量的放疗对早期乳腺癌患者的效果更好

JAMA Oncology:两项研究同时表明短疗程大剂量的放疗对早期乳腺癌患者的效果更好据发表于 JAMA Oncology的两项研究表明,与接受长疗程小剂量放疗的早期乳腺癌患者相比,接受短疗程大剂量放疗的毒副作用更小,生活质量更好。1.来自休斯顿德克萨斯大学的MD Anderson肿瘤中心的研究Dr. Shaitelman 及其同事分析了287名年龄在40岁及以上的早期乳腺癌女性,均接

Lancet:多导管近距离放疗辅助APBI治疗早期乳腺癌风险评估

在这个第三阶段,随机,非劣效性试验中,对0,I,IIA阶段的乳腺癌患者进行加速部分乳腺照射(APBI),将那些接受保乳治疗与全乳照射的患者进行了比较。在这里,研究人员展示了5年的随访结果。研究人员在七个欧洲国家16家医院和医疗中心做了一项3期,随机,非劣效性试验。1184例原位低风险扩散性导管乳腺癌接受保乳手术治疗的患者,随机接受全乳照射或使用多导管近距离放射治疗APBI。主要终点是局部复发。分析

早期乳腺癌微创治疗获突破性进展,这技术真的是帅呆了!

在我的印象里,我在上小学的时候,地方卫视里总会出现“不开刀、不住院、无痛苦”之类的广告词,以宣扬医院里新引进的微创治疗仪。我总觉得“不开刀、不住院、无痛苦”,已经被那些低劣的卫视广告玩儿坏了。今天我居然也要介绍一项“类似的”技术,好有魔幻主义色彩。12月8日,一年一度的圣安东尼奥乳腺癌研讨会(San Antonio Breast Cancer Symposium,SABCS)在德克萨斯州盛大召开。

Lancet:芳香化酶抑制剂 vs 他莫昔芬治疗早期乳腺癌

使用芳香化酶抑制剂或他莫昔芬作为早期乳腺癌的内分泌治疗的最佳方式仍存在不确定性。    研究人员对31920例绝经后患有雌激素受体阳性的早期乳腺癌的女性患者进行了个人数据的荟萃分析,该随机试验包括:第1组为芳香酶抑制剂 vs 他莫昔芬分别进行5年治疗;第2组为5年的芳香化酶抑制剂 vs 2〜3年的他莫昔芬然后应用芳香化酶抑制剂治疗到第5年;第3组为2—3年的他莫昔芬然